Organisation paid for research Program year 2025 Source: CMS Open Payments

Care United Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$814,301

104 payments

Through program year 2025, Care United Research, LLC is reported as receiving $814,301 in research payments, across 104 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $469,409 4
2024 Research $58,058 9
2023 Research $270,891 32
2022 Research $1,778 2
2021 Research $14,163 57

Breakdown

Who paid Research payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $498,656 5 payments
  2. Dexcom, Inc. $279,160 37 payments
  3. Roche Diagnostics Operations, Inc. $20,543 3 payments
  4. Novo Nordisk AS $15,942 59 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $442,551 1 payment
  2. Evaluation of the Dexcom Continuous Glucose Monitoring (CGM) System Protocol $169,534 14 payments
  3. Evaluation of Basal Insulin Initialization and Titration in People With Type2 Diabetes Wearing A Dexcom G6 Sensor $109,626 23 payments
  4. A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $22,269 1 payment
  5. Rd006263 $20,543 3 payments
  6. A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $18,498 1 payment
  7. Nn9924-4635 $15,193 13 payments
  8. A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $9,930 1 payment
  9. A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $5,409 1 payment
  10. Ex6018-4758 $749 46 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record